Company / EPS (Diluted)
SAB Biotherapeutics, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.68
FY2025
5-year range
-$7.64 / $0.74
FY2021-FY2025
Trend
+51.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-3.68.
Based on SEC 10-K filings.
-3.68 in FY2025.
Improved from $-4.31 to $-3.68 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 51.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.68 | +51.8% |
| FY2024 | -$7.64 | -77.3% |
| FY2023 | -$4.31 | - |
| FY2022 | - | - |
| FY2021 | $0.74 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026